In the literature, the PD-L1 expression in the tumors is often described to be a predictive biomarker for effective anti-PD-1 therapies [27]: accordingly PD-L1 expression was higher in Hep-55.1c tumor sections than iAST tumor sections (S5 Fig). The gene discussed is PDCD1; the disease is neoplasm.